August 25, 2020
Rakuten Medical’s sakigake -designated antibody drug conjugate (ADC) (cetuximab sarotalocan sodium), based on its photoimmunotherapy technology platform, as well as a host of other drugs, will come up for discussion by a key health ministry advisory committee on September 4...read more